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Abstract 
Receptors for regulatory peptides can be overexpressed by several diseases, in particular 
by neoplasms. This review summarizes th  current status of knowledge in this field, on 
the basis of in vitro receptor studies and with emphasis on receptors for somatostatin as 
well as for substance P (SP), vasoactive intestinal polypeptide (VIP), and cholecystokinin. 
It evaluates the existing and potential clinical implications f the findings for diagnosis 
and therapy and discusses the role of the pathologist in this context. 
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Introduction 
During the last decades, endocrine 
pathology has been involved in under- 
standing the origin, role, and diagnostic 
implications of the peptide hormones 
excessively synthesized and secreted by 
endocrine tumors. Recently, another basic 
aspect of endocrine function of these 
tumors has emerged: the high expression 
of membrane-bound receptors for several 
peptides. These receptors, potential new 
tumor markers, are of particular interest 
to pathologists because of both diagnostic 
and therapeutic implications. 
Membrane receptors are key molecules 
for cellular interactions as they represent 
the specific molecular targets of a particu- 
lar endogenous substance, which acts on a 
target issue. An adequate receptor status 
is, therefore, important for the normal 
homeostasis of an organ, whereas quanti- 
tative or qualitative alterations of the 
receptors may indicate the presence of a 
disease, or even represent the biochemical 
basis of that disease. Specific drugs designed 
to have a high affinity for these receptors 
can be used therapeutically. Receptors can 
also be used for diagnostic purposes, as 
targets for specific radiolabeled ligands 
designed as high affinity synthetic analogs 
of the corresponding endogenous substances. 
Peptide Hormones 
and Their Receptors 
The regulatory peptides (Table 1) r p- 
resent an interesting roup of molecules 
known to act usually on multiple targets 
in the human body, at extremely ow con- 
centrations [1]. Targets of these peptides 
are primarily the brain and the gastrointes- 
tinal tract, but include also the endocrine 
system, the kidneys, the immune, vascu- 
lar, and peripheral nervous systems. The e 
regulatory peptides control and modulate 
the function of almost all key organs and 
metabolic processes. The peptide action is 
mediated through specific membrane- 
bound receptors, usually of the type of 
G-protein coupled, seven transmembrane 
domains containing proteins. Receptor 
subtypes with their own ligand specificity 
and second messenger systems have been 
discovered for almost all peptides. This fact 
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Table 1. Major Regulatory Peptides 
Opioid peptides 
Substance P 
Gastrin 
Cholecystokinin 
Vasoactive intestinal peptide 
Pituitary adenylate cyclase activating 
peptide 
Alpha-melanocyte-stimulating hormone 
Arginine-vasopressin 
Oxytocin 
Angiotensin 
Calcitonin 
Endothelin 
Bradykinin 
Bombesin/gastrin-releasing peptide 
Neuropeptide Y 
Galanin 
Atrial natriuretic factor 
Neurotensin 
Secretin 
Somatostatin 
TRH 
LHRH 
CRF 
GHRH 
results in an increased iversification of the 
mode of action of particular peptides. 
For the pathologist and clinician alike, it 
is of interest to know which peptide receptor 
can be altered, in which type of pathology 
such alterations occur, and the practical con- 
sequences for their diagnostic work. Some 
of the salient findings in the peptide hor- 
mone receptor field, and the clinical conse- 
quences are summarized, with particular 
emphasis on somatostatin receptors. 
Somatostatin 
and Somatostatin Receptors 
Somatostatin exists as 14-amino acid 
(somatostatin- 14) or 28-amino acid (soma- 
tostatin-28) long peptide, present mainly 
in the central nervous ystem, the hypo- 
thalamo-pituitary system, the gastrointes- 
tinal tract, the exocrine and endocrine 
pancreas, and the immune system. It exerts 
primarily an inhibitory effect on a wide 
spectrum of physiological functions, 
including inhibition of peptide hormone 
secretion [2]. Somatostatin can thus be 
considered as a neurotransmitter, a neuro- 
hormone, or a local hormone acting via 
autocrine or paracrine mechanisms. More- 
over, somatostatin appears to play a role in 
cancer: In many animal tumor models and 
cultured tumor cell lines, somatostatin a d 
somatostatin analogs inhibit tumor 
growth. Further, octreotide, the first clini- 
cally used stable somatostatin analog, 
successfully controls hormonal hypersecre- 
tion in patients with pituitary tumors, 
carcinoids, and islet cell tumors, and may 
occasionally inhibit tumor growth as well. 
These somatostatin and octreotide actions 
are mediated by specific, high affinity 
somatostatin receptors located on the 
plasma membrane of the target cells. 
Indeed, the presence of somatostatin 
receptors has been demonstrated in various 
regions of the normal brain; the leptom- 
eninx; the anterior pituitary; the endocrine 
and exocrine pancreas; the mucosa of the 
gastrointestinal tract; the normal human 
kidney and the prostate; parts of the 
peripheral nervous ystem (gastrointestinal 
plexus); and cells of the immune and vas- 
cular systems [1]. To date five human 
somatostatin receptor subtypes st 1, sst 2, 
sst 3, sst 4, and sst 5 have been cloned and par- 
tially characterized. They have distinct, 
often overlapping patterns of expression. 
The subtypes belong to a superfamily of 
G-protein coupled receptors that can func- 
tionally couple to the inhibition ofadenylyl 
cyclase. Pharmacological studies showed 
that all five human subtypes bind soma- 
tostatin-14 and somatostatin-28 with high 
affinity. However, there are differences in 
the binding affinities of the structural 
analogs of somatostatin: For instance, 
octreotide binds with a high affinity to the 
sst 2 and sst 5 human receptor subtypes and 
with a moderate affinity to sst 3, but not to 
subtypes s h and sst 4 [3,4]. 
In Vitro Detection 
of Somatostatin Receptors 
in Human Tumors 
Within the last decade, it has been 
shown, surprisingly, that a wide variety of 
endocrine as well as "nonendocrine" human 
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Table 2. Incidence of Human Tumors that Express Somatostatin Receptors 
Neuroendocrine tumors (pituitary adenomas, ICC, 
carcinoids, paragangliomas, MTC, 
pheochromocytomas, SCLC) 
Tumors of the nervous ystem (astrocytomas, 
neuroblastomas, medulloblastomas, 
meningiomas) 
Renal cell carcinomas 
Malignant lymphomas 
Prostate cancers a 
Breast cancers 
Ovarian, pancreatic, b and colonic cancers 
NSCLC, glioblastomas, schwannomas 
High 
High 
High 
High 
High 
About 50% 
Low 
No receptors 
"No sst 2 (octreotide-preferring somatostatin receptors) but at least sstj is present [9]. 
~No sst 2, but sst I and sst 4 may be present [10]. 
tumors express somatostatin receptors 
(Table 2), as measured in vitro with 
radioligand binding techniques using 
125I-labeled somatostatin a alogs, either in 
tumor homogenates oron tumor sections 
(receptor autoradiography) [5]. 
The highest incidence of somatostatin 
receptors are observed in neuroendocrine 
tumors. Most GH- and TSH-producing 
pituitary adenomas and several non- 
secreting adenomas contain somatostatin 
receptors, as do many endocrine gastro- 
enteropancreatic tumors, pheochromocy- 
tomas, paragangliomas, medullary thyroid 
carcinomas, and small cell lung cancers 
(Table 2). Most of the aforementioned 
tumors belong to the group of apudomas 
(i.e., tumors thought to arise from the 
amine precursor uptake and decarboxyla- 
tion cell). These tumors have generally a
high density of somatostatin receptors, 
although a great individual variability is 
usually observed (e.g., more than a 10-fold 
difference in somatostatin receptor density 
within a particular tumor type). Therefore, 
it has been suggested that somatostatin 
receptors, especially of the octreotide-pre- 
ferring sst 2 subtype, are valuable markers 
for the diagnosis ofneuroendocrine tumors. 
For instance, the octreotide receptor sta- 
tus clearly differentiates between endocrine 
and exocrine pancreatic carcinomas, the latter 
being a/ways receptor-negative. However, also 
those neuroendocrine tumors that remain 
poorly differentiated (i.e., atypical cardnoids) 
appear to lack these receptors. Thus, it is pres- 
endy believed that primarily the well-differ- 
entiated neuroendocrine tumors express 
somatostatin receptors (Fig. 1). 
A second group of human tumors, origi- 
nating in the nervous ystem, frequently 
expresses somatostatin receptors (Table 2) 
[5], which is more than 80% of astrocyto- 
mas, a high percentage ofneuroblastomas, 
and all meningiomas. 
Third, malignant lymphomas, clearly 
not neuroendocrine tumors, have been 
recently identified as having a high inci- 
dence of somatostatin receptors. Thus, 
somatostatin receptors cannot be consid- 
ered exclusively as a neuroendocrine 
marker. More than 70% of renal cell car- 
cinomas, and approx 50% of breast tumors 
have also been shown to possess somatosta- 
tin receptors, including those breast umors 
with neuroendocrine characteristics. Con- 
versely, colorectal and ovarian tumors are 
characterized by a much lower incidence 
of somatostatin receptors. A large group 
of human neoplasms, including glioblas- 
tomas, nonsmall cell lung cancers, and 
many squamous cell carcinomas, do not 
express ignificant amounts of somatosta- 
tin receptors. Thus, somatostatin receptors 
are not "universal" markers for human 
neoplasms. 
Human tumors can also express differ- 
ent somatostatin receptor subtypes, as their 
normal tissue counterparts do [5,6]. Pitu- 
itary adenomas appear to express all five 
sst subtypes, with particularly high levels 
of  SSt 2 and sst 5 [7], as shown with reverse 
transcriptase PCR and ribonuclease pro- 
tection assay. Also, in situ hybridization for 
sst subtype mRNAs showed that various 
human tumor types can express one or sev- 
eral of the somatostatin receptor subtypes. 
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Fig. 1, Somatostatin receptors in an intestinal carcinoid tumor. (A) H&E stained 
section. Bar = 1 ram. (B) Autoradiogram showing total binding of 12Sl-[Tyr3]- 
octreotide. The tumor has a high density of somatostatin receptors (black areas). 
Nonspecific binding is negligible. 
The most frequently expressed subtype 
appears to be sst 2. This fact is biologically 
important, since sst 2 may act, under cer- 
tain circumstances, similar to  tumor sup- 
pressor gene: Expression f ss t  2 in BxPC3 
cells was indeed shown to massively inhibit 
their growth [8]. This high incidence ofsst 2 
is also extremely important for somatosta- 
tin receptor imaging and therapy of tumors 
with octreotide-like ligands because the ss t  2 
receptor has the highest affinity for 
octreotide among all somatostatin recep- 
tor subtypes. Conversely, it should be 
emphasized that there are several tumors 
that do not express octreotide-preferring 
somatostatin receptors (sst2), such as prostate, 
pancreatic, and probably ovarian adeno- 
carcinomas, as well as some insulinomas 
and medullary thyroid carcinomas [5,9,10]. 
These tumors will not be visualized by 
111In- [DTPA, DPhe 1]-octreotide imaging 
nor will they respond to octreotide therapy. 
A different type ofligand with high affin- 
ity for all subtypes, that is, structurally 
more closely related to somatostatin- 14or 
somatostatin-28 than to octreotide, would 
be required to overcome these difficulties. 
Somatostatin Receptors 
in Nonneoplastic Tissues 
Somatostatin receptors have been shown 
to mediate somatostatin actions in the 
immune, vascular, and nervous systems. 
Thus, it was not too mt/ch of a surprise to 
observe that nonneoplastic alterations of 
these systems may be associated with 
changes in the density of these receptors. 
One example is the florid granuloma in 
sarcoidosis or tuberculosis that expresses 
somatostatin receptors on epithelioid cells 
[11]; sclerosing/regressing granulomasa 
spontaneously or in response to treat- 
ment- -do not express somatostatin 
receptors any more. Also, affected joints 
in active rheumatoid arthritis express a high 
density of somatostatin receptors, prefer- 
entially located in synovial vessels (Fig. 2). 
Further, in inflammatory bowel disease, 
somatostatin receptors are primarily 
overexpressed in the vascular system [12]. 
Finally, veins located in areas urrounding 
different ypes of tumors can overexpress 
somatostatin receptors [13]. This could be 
the molecular basis of an indirect effect of 
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Fig. 2. Somatostatin and substance P receptors in adjacent sections of synovial 
tissue from a rheumatoid arthritis patient. (A) Immunohistochemical demonstra- 
tion of numerous vessels (FVlll-related antigen). Bar = 1 ram. (B) Autoradiogram 
showing total binding of ~2SI-Bolton-Hunter substance R Nonspecific binding is neg- 
ligible. Vessels are strongly substance P receptor-positive. (C) H&E stained, adjacent 
section to A Bar = 1 mm. (D) Autoradiogram showing total binding of 
12Sl-[Tyr3]-octreotide. Nonspecific binding is negligible. The veins are somatostatin 
receptor-positive. 
somatostatin on tumor growth by alter- 
ation of local hemodynamic processes. 
However, the reason for the overexpression 
ofsomatostatin receptors either in the ves- 
sels in inflammatory conditions or in 
tumors, has not yet been elucidated. 
patient and subsequent whole-body 
gamma camera scanning, has been 
developed and is now widely used as an 
efficient method for the localization of 
somatostatin receptor-positive tumors 
and their metastases, in particular GEP 
tumors [14]. 
3. In pituitary and GEP tumors, the 
somatostatin receptors are functional. 
Thus, the presence and density of 
somatostatin receptors correlate with 
the degree of inhibition of excessive 
hormone release by octreotide. The 
tumoral somatostatin receptor status 
can clearly be considered to be a pre- 
dictive factor for the therapeutic effi- 
cacy of octreotide [15]. 
4. In neuroblastomas, nd possiblyin a sub- 
group of breast tumors, the somatostatin 
receptor status may have a prognostic 
value. Moertel et al. have shown indeed, 
an inverse relationship between the pres- 
ence ofsomatostatin receptors and N-myc 
oncogene xpression in neuroblastomas 
[16]; in addition, the presence of soma- 
tostatin receptors in more than 60% of 
neuroblastomas clearly correlates with a 
favorable prognosis [16], a characteristic 
also observed by others [17]. 
5. Recent preliminary studies uggest that 
tumors with a high receptor density (i.e., 
GEP tumors) can be successfully treated 
with radiotherapy using radiolabeled 
somatostatin a alogs [18]. 
Clinical Implications 
What are the most important diagnos- 
tic, therapeutic, and prognostic implica- 
tions of the aforementioned results? 
1. The somatostatin receptor is a marker 
for differentiated neuroendocrine tumors, 
in vitro or in vivo. 
2. In vivo somatostatin receptor scintigra- 
phy, based on the iv injection of an 
111in.labele d somatostatin a alog to the 
Role of the Pathologist 
What is the role of the pathologist in 
these issues? By evaluating in vitro soma- 
tostatin receptors in tissue sections from 
surgical biopsies, the pathologist may play 
a decisive role in tumor typing and in the 
search of diagnostic, prognostic, or predic- 
tive clues such as increased ensities of 
somatostatin receptors. In addition, the 
correlation of structural changes--for 
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instance inflammation--and functional 
parameters may offer unique insights in 
basic mechanisms of disease. However, the 
somatostatin receptor measurement in 
diagnostic pathology has not yet been 
developed as a standard method. 
There are two probable reasons for that. 
The first is related to the cumbersome 
method itself (i.e., in vitro receptor auto- 
radiography on tissue sections) [1]. This is 
a powerful and very specific method to 
analyze the binding of 125-iodine labeled 
radioligands totheir receptors in 10-20 
thick tissue sections, but the technique is
time-consuming and requires pecific labo- 
ratory facilities, expertise, and personnel 
acquainted with radioisotopic studies [1]. 
Rather than investing in these techniques, 
many surgical pathologists may prefer to 
wait for the development of adequate 
somatostatin receptor antibodies to per- 
form immunohistochemistry in formalin- 
fixed sections. The second reason is related 
to the impressively rapid development of
in vivo somatostatin receptor scintigraphy. 
In most cases, it is tempting for the clini- 
cian to take advantage of this relatively 
simple in vivo technique rather than to 
request an in vitro somatostatin receptor 
evaluation. The in vivo scintigraphy gives 
obviously more clinical (or clinically usable) 
information than in vitro measurements. 
Not only does it measure the somatostatin 
receptor status of diseased tissues, but also 
their localization in the patient. The 
development of a FDA-approved kit 
(Octreoscan | has contributed to the 
worldwide use of this in vivo method. The 
in vitro receptor autoradiography meth- 
ods, conversely, have a more experimen- 
tal character, but allow the histological 
localization of somatostatin receptors 
(e.g., in blood vessels) and thus provide a 
unique basis for the correct histopatho- 
logic interpretation of scintigraphic 
observations made in vivo. 
Evaluation of Other 
Peptide Receptors in Diseases 
Somatostatin receptors are not expressed 
in all neoplasms. Some of the most devas- 
tating tumors do not express ignificant 
amounts ofsomatostatin receptors. There- 
fore, it is mandatory to search in vitro for 
overexpression fother egulatory peptide 
receptors [1]. The first promising findings 
are emerging and are summarized in the 
following paragraphs. 
Thus, in a recent study, we identified a
high prevalence of vasoactive intestinal 
polypeptide (VIP) receptors in almost all 
human epithelial tumors [19], including 
somatostatin receptor-negative tumors. 
These observations are in keeping with the 
recent report on localization of tumors by 
VIP receptor scintigraphy inpatients [20]. 
We have also found that receptors for 
the peptide substance P (SP) are expressed 
in many neoplasms, such as in glial tumors, 
medullary thyroid carcinomas, and breast 
tumors, but rarely in gastrointestinal 
tumors or lymphomas [21]. Interestingly, 
all tumors, including the receptor-negative 
ones, displayed many SP receptors in 
tumoral and peritumoral vessels [21]. An 
overexpression of SP-R in vessels had 
been reported earlier by Mantyh et al. [22] 
in inflammatory bowel diseases and by 
Walsh et al. [23] in rheumatoid arthritis. 
Therefore, a dual approach with SP ana- 
logs, that is, based on the tumoral and 
vascular receptor expression, may be con- 
sidered [21] for the diagnosis or treatment 
of these diseases. 
Finally, there is recent evidence of an 
overexpression f CCK-B/gastrin receptors 
in most MTC and in SCLC [24,25]. Con- 
versely, neither differentiated thyroid can- 
cers nor nSCLC express CCK-B/gastrin 
receptors. Therefore, CCK-B/gastrin re- 
ceptors could play an important role for 
the "in vivo typing" of thyroid and lung 
tumors, before histopathological evaluation. 
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SS VIP SP CCK-B CCK-A 
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nSCLC 
Fig. 3. Incidence of various peptide receptors in selected human tumor types. The 
incidence (in %) of the tumors expressing the various receptors i given for two 
types of tumors. The results are adapted from [19,21,24,29]. SS-R, VIP-R, SP-R, and 
CCK-R data are from different patient groups, and thus represent a statistical rather 
than individual positivity for the tumors. Flat histogram means absence of the 
respective receptor in the corresponding tumor. 
Gastrin strongly stimulates cell proliferation. 
Thus, gastrin receptors may be involved in 
the pathogenesis of these tumors, and 
CCK-B/gastrin receptor antagonists might
be of therapeutic value [24,25]. 
Thus, multiple peptide receptors can be 
expressed by individual human tumors. 
Preliminary results, seen in Fig. 3, which 
compare the incidence rate of several pep- 
tide receptors in selected tumors, seem to 
indicate that a highly variable, but perhaps 
tumor type-specific receptor attern, exist 
among these tumors. Medullary thyroid 
carcinomas, for example, may express 
receptors for substance P, somatostatin, and 
gastrin (Figs. 3 and 4), but lackVIP recep- 
tors. Conversely, nonsmall cell ung carci- 
nomas may often express VIP receptors, 
but rarely receptors for substance P, soma- 
tostatin, or gastrin (Fig. 3). Since the num- 
ber of existing regulatory peptides is large, 
it is likely that several other peptide recep- 
tors may be identified in the near future in 
high incidence and high density in specific 
diseases. This may allow to perform in vitro 
I 
C_ . .  _ . .  
r 
Fig, 4, Multiple peptide receptors expressed by a 
medullarythyroid carcinoma. (A) H&E stained section. 
Bar = 1 mm. (B) Autoradiogram showing total 
binding of 1251-gastrin. (C) Autoradiogram showing 
total binding of ~zSI-substance P. (D) Autoradiogram 
showing total binding of 'ZSl-[Tyr~]-octreotide. The 
tumor expresses CCK-B/gastrin-, substance P-, and 
somatostatin-receptors concomitantly. 
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Diagnosis Therapy: growth inhibition 
| 
A=antagonist 
Fig. 5. Diagnostic and therapeutic applications of the multiple peptide receptors 
expressed by individual tumors. (A) Tumor diagnosis using a cocktail of radiola- 
beled (*) peptides (specific binding) for in vivo signal amplification in thetumor. 
(B) Tumor growth inhibition based on the concomitant therapeutic use of mul- 
tiple peptide analogs, either agonists of growth-inhibiting peptides (SS) or 
antagonists (= A) of growth-stimulating peptides (VIP, SP, gastrin). 
or in vivo tumor "typing" by determining 
a "profile" characterized by different expres- 
sions of several peptide receptors. This 
identification of tumor- or disease-specific 
receptor phenotypes could thus provide 
specific targets for diagnostic in vivo 
imaging and, possibly, for therapy [1]. 
Of course, peptides are not the only regu- 
lators of a cell; growth factors, cytokines, 
and other molecules also play a major regu- 
latory role and are able to "cross-talk" with 
peptides to modulate cell responses. Growth 
factor and cytokine receptors are also altered 
in neoplastic and nonneoplastic diseases 
[26-28]. These alterations will affect the
interaction of growth factors and cytokines 
with peptides, and influence diagnostic and 
therapeutic strategies. 
Future Developments 
A promising strategy will be to evaluate 
and take advantage of the simultaneous 
expression of several peptide receptors in a 
given tumor type. This receptor pheno- 
typing of individual tumors may lead to 
novel diagnostic and therapeutic possibili- 
ties: First, he use of an intravenous injec- 
tion of a cocktail ofpeptide radioligands that 
bind specifically to a given tumor may 
massively increase the signal given by 
tumors canned in vivo (Fig. 5A); second, 
the simultaneous therapeutic use of sev- 
eral peptide analogs acting synergistically 
against umor proliferation could consid- 
erably improve the efficacy of peptide 
therapy (Fig. 5B). Since it can be foreseen 
that such a "receptor phenotyping" of 
individual tumors will be difficult and 
costly to perform in vivo, it is likely that 
this evaluation, which can be done with 
in vitro receptor autoradiography on small 
biopsies, will be added to the armamen- 
tarium of the diagnostic pathologist, espe- 
cially if rapid and reliable techniques to 
reveal receptors for peptides (i.e., using 
adequate antibodies against he various 
peptide receptors) become available. 
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